122 related articles for article (PubMed ID: 29023786)
21. Andersen-Tawil syndrome.
Weir RA; Petrie CJ; Murday V; Findlay IN
Int J Cardiol; 2011 Apr; 148(1):e13-5. PubMed ID: 19223265
[TBL] [Abstract][Full Text] [Related]
22. Long-term flecainide therapy in type 3 long QT syndrome.
Chorin E; Taub R; Medina A; Flint N; Viskin S; Benhorin J
Europace; 2018 Feb; 20(2):370-376. PubMed ID: 28339995
[TBL] [Abstract][Full Text] [Related]
23. Sudden death of a horse with supraventricular tachycardia following oral administration of flecainide acetate.
Dembek KA; Hurcombe SD; Schober KE; Toribio RE
J Vet Emerg Crit Care (San Antonio); 2014; 24(6):759-63. PubMed ID: 25388866
[TBL] [Abstract][Full Text] [Related]
24. Combination of flecainide and propranolol for congenital junctional ectopic tachycardia.
Imamura T; Tanaka Y; Ninomiya Y; Yoshinaga M
Pediatr Int; 2015 Aug; 57(4):716-8. PubMed ID: 25809220
[TBL] [Abstract][Full Text] [Related]
25. Use of flecainide for refractory atrial tachycardia of pregnancy.
Ahmed K; Issawi I; Peddireddy R
Am J Crit Care; 1996 Jul; 5(4):306-8. PubMed ID: 8811156
[TBL] [Abstract][Full Text] [Related]
26. Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation.
Delannoy E; Sacher F; Maury P; Mabo P; Mansourati J; Magnin I; Camous JP; Tournant G; Rendu E; Kyndt F; Haïssaguerre M; Bézieau S; Guyomarch B; Le Marec H; Fressart V; Denjoy I; Probst V
Europace; 2013 Dec; 15(12):1805-11. PubMed ID: 23867365
[TBL] [Abstract][Full Text] [Related]
27. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade.
Padfield GJ; AlAhmari L; Lieve KV; AlAhmari T; Roston TM; Wilde AA; Krahn AD; Sanatani S
Heart Rhythm; 2016 Feb; 13(2):609-13. PubMed ID: 26416620
[No Abstract] [Full Text] [Related]
28. KCNJ2 variant of unknown significance reclassified as long QT syndrome causing ventricular fibrillation.
Obeyesekere MN; Klein GJ; Conacher S; Krahn AD
Can J Cardiol; 2011; 27(6):870.e11-3. PubMed ID: 21875779
[TBL] [Abstract][Full Text] [Related]
29. Magnetocardiographic evaluation of nonarrhythmogenic flecainide-induced electrocardiographic T-wave inversion.
Brisinda D; Sorbo AR; La Brocca L; Fenici R
Anatol J Cardiol; 2017 Apr; 17(4):337-339. PubMed ID: 28466829
[No Abstract] [Full Text] [Related]
30. Hypokalemic periodic paralysis, facial dysmorphism and ventricular arrhythmia (clinical triad of Andersen-Tawil syndrome).
Thakkar M; Biswas TK; Desle HB
J Assoc Physicians India; 2012 Nov; 60():56-8. PubMed ID: 23767205
[TBL] [Abstract][Full Text] [Related]
31. Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation.
Brugada J; Pappone C; Berruezo A; Vicedomini G; Manguso F; Ciconte G; Giannelli L; Santinelli V
Circ Arrhythm Electrophysiol; 2015 Dec; 8(6):1373-81. PubMed ID: 26291334
[TBL] [Abstract][Full Text] [Related]
32. ST-segment elevation in a patient receiving flecainide.
Chung-Esaki H; Tabas J; Goldschlager N
Arch Intern Med; 2011 Jan; 171(1):11-3. PubMed ID: 21220653
[No Abstract] [Full Text] [Related]
33. Andersen-Tawil syndrome presenting as premenstrual periodic paralysis.
Parihar J; Chakraborty P; Kaul B
Muscle Nerve; 2021 Jan; 63(1):E5-E6. PubMed ID: 33094497
[No Abstract] [Full Text] [Related]
34. Brugada-type ECG pattern in patients treated with oral flecainide for lone atrial fibrillation: is there any clinical implication?
Letsas KP; Weber R; Arentz T; Kalusche D
Hellenic J Cardiol; 2009; 50(4):338-9. PubMed ID: 19622506
[No Abstract] [Full Text] [Related]
35. Electrophysiologic effects and therapeutic efficacy of intravenous flecainide for termination of paroxysmal supraventricular tachycardia.
Gambhir DS; Bhargava M; Arora R; Khalilullah M
Indian Heart J; 1995; 47(3):237-43. PubMed ID: 7558090
[TBL] [Abstract][Full Text] [Related]
36. [Andersen-Tawil syndrome: a review of its clinical and genetic diagnosis with emphasis on cardiac manifestations].
Márquez MF; Totomoch-Serra A; Vargas-Alarcón G; Cruz-Robles D; Pellizzon OA; Cárdenas M
Arch Cardiol Mex; 2014; 84(4):278-85. PubMed ID: 25270337
[TBL] [Abstract][Full Text] [Related]
37. An unusual case of flecainide-induced QT prolongation leading to cardiac arrest.
Oguayo KN; Oyetayo OO; Costa SM; Mixon TA
Pharmacotherapy; 2014 May; 34(5):e30-3. PubMed ID: 24510469
[TBL] [Abstract][Full Text] [Related]
38. The use of flecainide in critical neonates and infants with incessant supraventricular tachycardias.
Ergül Y; Özyılmaz İ; Saygı M; Tola HT; Akdeniz C; Tuzcu V
Turk Kardiyol Dern Ars; 2015 Oct; 43(7):607-12. PubMed ID: 26536985
[TBL] [Abstract][Full Text] [Related]
39. [The action of intravenous flecainide in experimental ventricular arrhythmias].
de Micheli A; Medrano GA; Casanova JM
Arch Inst Cardiol Mex; 1995; 65(5):403-12. PubMed ID: 8678696
[TBL] [Abstract][Full Text] [Related]
40. A peculiar case of palpitations and syncope.
Cheung CC; Scheinman M; Lee BK
Heart Rhythm; 2022 Mar; 19(3):505-507. PubMed ID: 35227417
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
